May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Quality of Life in Patients With Age-Related Macular Degeneration Undergoing Photodynamic Therapy With Verteporfin
Author Affiliations & Notes
  • L.D. Slakter
    Vitreous Retina Macula Consultants of New York, New York, NY, United States
  • J.S. Slakter
    Vitreous Retina Macula Consultants of New York, New York, NY, United States
  • Footnotes
    Commercial Relationships  L.D. Slakter, None; J.S. Slakter, Novartis Ophthalmics F, R; QLT Inc. F, R.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 1800. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L.D. Slakter, J.S. Slakter; Quality of Life in Patients With Age-Related Macular Degeneration Undergoing Photodynamic Therapy With Verteporfin . Invest. Ophthalmol. Vis. Sci. 2003;44(13):1800.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To examine the effects of exudative age-related macular degeneration (AMD) on the quality of life (QoL) of patients undergoing photodynamic therapy (PDT) with verteporfin. Methods: This prospective study utilized an expanded NEI-VFQ 25 QoL Questionnaire in conjunction with an additional "Well-Being" survey administered to consecutive patients with exudative AMD undergoing a first treatment with PDT. Demographic data was collected including age, gender, visual acuity of treated and fellow eye, angiographic classification of choroidal neovascularization (CNV) in the treated eye, and the status of the fellow eye. The questionnaire and survey were re-administered at 6-month follow up intervals to assess the effects of treatment. Results: To date, 110 patients have been enrolled in the study. Age ranged from 51 to 94 (mean 77.2 years). 40 were male (36%) and 70 female (64%). Baseline visual acuity in the treated eye ranged from 20/20 to 20/800 (mean 20/200). Baseline visual acuity in the fellow eye ranged from 20/20 to 20/800 (mean 20/150). Baseline fluorescein angiography demonstrated predominantly classic CNV in 55 eyes (50%), minimally classic CNV in 4 eyes (3.6%), and occult only CNV in 51 eyes (46.4%). 54 fellow eyes (49.1%) demonstrated advanced AMD, 47 eyes (42.7%) showed non-exudative disease, 3 eyes (2.7%) were considered normal, and 6 eyes (5.5%) exhibited non-AMD related abnormalities. The average composite NEI-VFQ 25 score for all patients at baseline was 73.45. A comparable normative composite value is 93. For those patients with unilateral vision loss (fellow eye non-exudative or normal) the average composite score was 76.04 compared to a composite score of 68.39 in those with bilateral vision loss. Subscale scoring and changes in NEI-VFQ 25 scores at follow up examination will be presented. Conclusions: Exudative AMD has a profound effect on the QoL of patients with both unilateral and bilateral disease. The utility of PDT on patient QoL can be evaluated using these psychosocial questionnaires.

Keywords: age-related macular degeneration • quality of life • photodynamic therapy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×